MDS Research To Be Presented At The European Hematology Association’s Congress (EHA 2012)
Published: Jun 14, 2012 12:27 pm
Physicians and researchers, including those specializing in myelodysplastic syndromes, are gathering at the 17th Congress of the European Hematology Association (EHA) to share the latest findings in the field. The meeting starts in Amsterdam today and will run through Sunday, June 17.
The MDS Beacon will report on the most important new findings related to myelodysplastic syndromes (MDS) over the next couple of weeks.
The research presented at the meeting will cover all areas of hematology, which is the study of blood, blood-forming organs, and blood-related diseases, including MDS.
Today, researchers will have the opportunity to attend scientific working groups to discuss specific challenges and advances in their respective fields. The MDS scientific working group includes discussions on MDS and inherited bone marrow failures, occupational and environmental factors in MDS, and therapy-related MDS.
Education sessions will be held during the day tomorrow. These sessions will give practicing physicians an opportunity to maintain and develop professional knowledge and skills in their fields. During the MDS education session, doctors will hear about the biology and clinical aspects of MDS as well as the integration of genetic mutations in the diagnosis and risk assessment of MDS.
On Saturday, researchers will present the latest findings on molecular advances in MDS. The topics to be discussed include the spectrum and structure of genetic mutations in MDS, the effects of certain genetic mutations on MDS prognosis, and the effect of a specific mutation (SF3B1) on red blood cell production and excess iron.
Also on Saturday, two MDS experts will be discussing the usefulness of iron chelation therapy in MDS during a so called “lunch-time debate.”
On Sunday, the final day of the congress, translational and clinical research in MDS will be discussed. Researchers will present the latest findings from a clinical trial of Promacta (eltrombopag) for the treatment of low platelet counts. Another presentation will report on clinical features, treatment, and prognosis of patients with monosomy 7. Researchers will also talk about the effects of high levels of DNA methylation on prognosis. Both Dacogen (decitabine) and Vidaza (azaciditine) are specifically designed to counteract DNA methylation.
In addition, attendees will also have the opportunity to view and discuss posters about the latest MDS research during dedicated MDS poster sessions to be held Friday through Sunday.
For more information on the 17th Congress of EHA, including presentation abstracts and attendance information, please see the EHA meeting website.
- MDS Research To Be Presented At EHA Congress
- MDS Research Presented At The 15th Congress Of The European Hematology Association (EHA 2010)
- Latest MDS Research Findings To Be Presented At The American Society Of Hematology Annual Meeting (ASH 2011)
- SRSF2 Mutations In MDS Patients May Be Associated With Shorter Survival (EHA 2012)
- MDS Beacon To Report Latest MDS Research From Upcoming American Society Of Hematology Annual Meeting (ASH 2012)